Gilead is committed to making information about our clinical research publicly available. We believe that transparency advances science and medicine and is in the best interest of the individuals who use our products and providers who prescribe them.
- We strive to ensure that our research practices are transparent, responsible, and fully compliant with applicable laws and regulations.
- We have staff dedicated to ensuring the timely registration of clinical trials, communication of research results, and release of clinical trial documents.
- We collaborate with external medical experts and scientific researchers to advance clinical research and enhance public health.
Gilead provides this information consistent with the need to protect patient privacy, publication rights, and proprietary information.
Details regarding our pipeline of investigational medicinal products can be found on our pipeline page.
If you have a specific inquiry regarding our Clinical Trial Disclosure and Data Transparency commitment or practices, please contact us at
Clinical Trial Registration
In cell therapy, we are currently investigating multiple indications in the axicabtagene ciloleucel and the KTE-C19 development program as well as for our TCR pipeline and second-generation technology. Our areas of research include a variety of blood cancers and solid tumors.
Gilead ensures that applicable clinical trials are registered prior to the first patient being consented for the study. Registration prior to first patient consent is aligned with the International Committee of Medical Journal Editors (ICMJE) guidelines.
Posting of Clinical Trial Results
Gilead discloses summary clinical trial results, regardless of the outcome of the trial, as required by law and/or regulation. This includes Gilead-sponsored clinical trials that have been registered on publicly accessible clinical trial registries.
In the USA, summary results are posted on
- For studies with a primary completion date prior to January 18, 2017 and related to products that have not yet been approved or are being investigated for new uses, Gilead posts summary results on
ClinicalTrials.gov(CTgov) within 30 days of receiving regulatory approval. For studies with a primary completion date after January 18, 2017 and related to products that have not yet been approved or are being investigated for new uses, Gilead posts summary results within 12 months of primary completion date regardless of approval status.
In Europe (EU and EEA), summary results are posted on the European Union Clinical Trial Register (EU-CTR) no later than 12 months after the trial Last Patient Last Visit Date (LPLV) for trials with adult participants and no later than six months after the trial LPLV Date for trials with pediatric participants regardless of approval status.
In Countries outside the US and the EU, Gilead adheres to all mandatory results posting requirements in accordance with the country specific guidelines for that region.
Some of the content on this page is not intended for users outside